Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 324-331

  Tynell, Elsa ^b   Aurelius, Elisabeth ^b   Brandell, Astri ^b   Julander, Inger ^b   Wood, Martin ^b   Yao, Qing Yun ^b   Rickinson, Alan ^b   Åkerlund, Börje ^b   Andersson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; HETEROPHILE ANTIBODY; HLA ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PLACEBO; PREDNISOLONE; VIRUS CAPSID ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; INFECTIOUS MONONUCLEOSIS; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE TRANSFORMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OROPHARYNX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA; TABLET; VIRUS INHIBITION; VIRUS SHEDDING;

EID: 0029973744     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.324     Document Type: Article

References (31)

1. Straus SE. Acute progressive Epstein-Barr virus infections. Annu Rev Med 1992;43:437-49.
2. Sixbey JW, Lemon SM, Pgano JS. A second site of Epstein-Barr virus shedding: the uterine cervix. Lancet 1986;2:1122-4.
3. Rickinson AB. Cellular immunological responses to the virus infection. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus: recent advances. New York: Wiley Publications, 1990:75-115.
4. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl) guanine] on Epstein-Barr virus DNA replication. J Virol 1980;34:560-8.
5. Pagano JS, Sixbey JW, Lin JC. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother 1983;12(suppl B):113-21.
6. Andersson J, Britton S, Ernberg I, et al. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis 1986;153:283-90.
7. Andersson J, Skoldenberg B, Henle W, Emberg I. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection 1987;15:14-20.
8. van der Horst C, Joncas J, Ahronheim G, et al. Lack of effect of peroral acyclovir for the treatment of infectious mononucleosis. J Infect Dis 1991;164:788-92.
9. Prout C, Dalrymple W. A double-blind study of eighty-two cases of infectious mononucleosis treated with corticosteroids. J Am Coll Health Assoc 1966;15:62-6.
10. Bender CE. The value of corticosteroids in the treatment of infectious mononucleosis. JAMA 1967;15:529-31.
11. Klein EM, Cochran JF, Buck RL. The effects of short-term corticosteroid therapy on the symptoms of infectious mononucleosis pharyngotonsillitis: a double-blind study. J Am Coll Health Assoc 1969;17:446-52.
12. Collins M, Fleisher G, Kreisberg J, Fager S. Role of steroids in the treatment of infectious mononucleosis in the ambulatory college student. J Am Coll Health 1984;33:101-5.
13. Waldo RT. Neurologic complications of infectious mononucleosis after steroid therapy. South Med J 1981;74:1159-60.
14. McGowan JE Jr, Chesney PJ, Crossley KB, LaForce FM. From the Infectious Diseases Society of America: Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J Infect Dis 1992;165:1-13.
15. Andersson J, Ernberg I. The management of Epstein-Barr virus infections. Am J Med 1988;85:107-15.
16. Davidsohn I, Lee CL. Serologic diagnosis of infectious mononucleosis. A comparative study of five tests. Am J Clin Pathol 1964;41:115-25.
17. Henle W, Henle G, Andersson J, et al. Antibody responses to EBNA-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987;84:570-5.
18. Reedman BM, Klein G, Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. Int J Cancer 1973;11:499-520.
19. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990:1889-920.
20. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993;118:45-58.
21. Williams ML, Loughran TP Jr, Kidd PG, Starkebaum GA. Polyclonal proliferation of activated suppressor/cytotoxic T cells with transient depression of natural killer cell function in acute infectious mononucleosis. Clin Exp Immunol 1989;77:71-6.
22. Kroes ACM, Brouwer ML, van Batenburg M, Balk AHMM. Primary Epstein-Barr virus infection in an immunosuppressed patient: symptoms, serology, and T cell response. J Infect Dis 1991;163:1385-7.
23. Marray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV); implications for the immune control of EBV positive malignancies. J Exp Med 1992;176:157-68.
24. Chapman CJ, Spellerberg MB, Smith GA, Carter SJ, Hamblin TJ, Stevenson FK. Autoanti-red cell antibodies synthesized by patients with infectious mononucleosis utilize the VH4-21 gene segment. J Immunol 1993;151:1051-61.
25. Masucci MG, Emberg I. Epstein-Barr virus; adaptation to a life within the immune system. Trends Microbiol 1994;2:125-30.
26. Linde A, Andersson B, Svenson SB, et al. Serum lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:91-100.
27. Andersson J, Andersson U. Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral blood. Clin Exp Immunol 1993;92:7-13.
28. Andersson J, Björk L, Ågren K, Litton M, Abrams J, Andersson U. Concomitant production of 19 different cytokines in human tonsil tissue. Immunology 1994;83:16-24.
29. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug, valaciclovir, after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
30. Bacon TH, Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrob Agents Chemother 1995;39:1599-602.
31. Luedke CE, Cerami A. Interferon-γ overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. J Clin Invest 1990;86:1234-40.